Genta-Aventis Case Study: Failing Strategies Within Late Stage Vertical Licensing
| Hōputu: | Tāhiko Hautaka |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MarketLine, a Progressive Digital Media business
|
| Urunga tuihono: | Full text available on EBSCOhost[Nov 2005-Nov 2005 |
Ngā tūemi rite
IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
Roche-Kosan Case Study: Successful Early Licensing Strategies
Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
Aventis SWOT Analysis
Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio
Sanofi-Aventis SWOT Analysis
Licensing Loyalty
mā: McLeod
mā: McLeod
License to Play
mā: Daliot-Bul
mā: Daliot-Bul
License to Wed
mā: Richman
mā: Richman
Licensing Journal
Failing Families, Failing Science
mā: Lincoln
mā: Lincoln
Licensed Practical Nurse
Vertical Reefs
mā: Wicksten
mā: Wicksten
Lipitor Case Study: Lifecycle Management Strategies
Failed Frontiersmen
mā: Donahue
mā: Donahue
Words Fail
mā: Dickinson
mā: Dickinson
The Revolution that Failed
mā: Fairclough
mā: Fairclough
Failed Evidence
mā: Harris
mā: Harris
Failed Promises
mā: Konisky
mā: Konisky
IPO Exit Strategies Case Study: Undertaking a Successful IPO Exit Strategy
Staging Harmony
mā: Brokaw
mā: Brokaw
Staging Asia
mā: Kuruppath
mā: Kuruppath
Setting the Stage
mā: Hays
mā: Hays
Subversive Stages
mā: Komporaly
mā: Komporaly
Staging Revolution
mā: Fan
mā: Fan
Occupying the Stage
mā: Bredeson
mā: Bredeson
Staging Family
mā: Mullenneaux
mā: Mullenneaux
Staging the Amistad
mā: Christensen
mā: Christensen
On Stage Alone
mā: Gitelman
mā: Gitelman
Staging Ghana
mā: Schauert
mā: Schauert
Stage for Action
mā: Dail
mā: Dail
The Stages of Memory
mā: Young
mā: Young
Ngā tūemi rite
- IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
- Roche-Kosan Case Study: Successful Early Licensing Strategies
- Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
- Aventis SWOT Analysis
- Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio